Hepatitis in the organ transplant patient

Current Opinion in Organ Transplantation

Volumn 6, Issue 4, 2001, Pages 295-300

  Chan, Andrew T ^a   Chung, Raymond T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; AZATHIOPRINE; CYCLOSPORIN; FAMCICLOVIR; GANCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; RIBAVIRIN;

ALLOGRAFT; BLOOD TRANSFUSION; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HEMOLYTIC ANEMIA; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOCOMPETENCE; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LONG TERM CARE; NONHUMAN; ORGAN TRANSPLANTATION; OUTCOMES RESEARCH; POSTOPERATIVE INFECTION; RECIPIENT; RECURRENT VIRUS INFECTION; REVIEW; VIREMIA; VIRUS ACTIVATION; VIRUS REACTIVATION; VIRUS TYPING;

EID: 0035687102     PISSN: 10872418     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075200-200112000-00004     Document Type: Review

References (69)

1. National surveillance of dialysis associated diseases in the United States, 1995
2. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B infection
3. Impact of hepatitis B and C virus on kidney transplantation outcome
4. Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients
5. An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation
6. Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients
7. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients
8. Treatment of fibrosing cholestatic hepatitis with lamivudine
9. Results on preemptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: Comparison with salvage treatment after hepatic dysfunction with HBV recurrence
10. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation
11. Nephrotic syndrome after liver transplantation in a patient with hepatitis C virus-associated glomerulonephritis
12. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients
13. Association of hepatitis C virus infection with mortality and graft survival in kidney-pancreas transplant recipients
14. The impact of azathioprine on chronic viral hepatitis in renal transplantation: A long-term, single-center, prospective study on azathioprine withdrawal
15. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: Response to interferon-alpha therapy
16. Chronic viral hepatitis in renal transplant recipients with allografts functioning for more than 20 years
17. Association of hepatitis C virus infection with mortality and graft survival in kidney-pancreas transplant recipients
18. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment
19. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years
20. Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil
21. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease
22. Hepatic histologic findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis
23. Liver transplantation in European patients with the hepatitis B surface antigen
24. Retransplantation for hepatitis B-a multicenter experience
25. Hepatitis B and C coinfections and persistent hepatitis B infections: Clinical outcome and liver pathology after transplantation
26. High pre-treatment serum hepatitis B virus titer predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation
27. Interferon alfa for recurrent hepatitis B infection after liver transplantation
28. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B
29. Lamivudine without HBlg for prevention of graft reinfection by hepatitis B : Long-term follow-up
30. Lamivudine for hepatitis B in liver transplantation: A single-center experience
31. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis
32. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation
33. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
34. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy
35. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B
36. Long-term experience with lamivudine therapy for hepatits B virus infection after liver transplantation
37. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient
38. Famciclovir treatment in transplant recipients with HBV-related liver disease: Disappointing results
39. Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation
40. Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation
41. Additional interferon alpha for lamivudine resistant hepatitis B infection after liver transplantation: A preliminary report
42. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation
43. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen
44. Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation
45. Long-term outcome of hepatitis C infection after liver transplant
46. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation
47. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C
48. Predictors of patient and graft survival following liver transplantation for hepatitis C
49. HCV-related fibrosis progression following liver transplantation: Increase in recent years
50. Hepatitis C infection in patients undergoing liver retransplantation
51. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury
52. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation
53. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation
54. Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate
55. Pretransplantation hepatitis C quasispecies may be predictive of outcome after liver transplantation
56. Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation
57. Relation between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation
58. Hepatitis C virus genotypes in liver transplant patients: Impact on posttransplant recurrence, infections, response to interferon-[alpha] therapy and outcome
59. Interferon alpha therapy for hepatitis C virus infection after liver transplantation
60. Daily interferon therapy for hepatitis C virus infection in liver transplant recipients
61. Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation
62. Pilot study of the combination of interferon alpha and ribavirin as therapy of recurrent hepatitis C after liver transplantation
63. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation
64. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin
65. Successful rescue of severe recurrent hepatitis C with interferon and ribavirin in a liver transplant patient
66. Prophylaxis against recurrence after liver transplantation: Effect of interferon and ribavirin combination
67. Interferon-[alpha] for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: A prospective, randomized controlled trial
68. Combination therapy of interferon alpha-2b and ribavirin for recurrent hepatitis C after liver transplantation
69. Peginterferon alfa-2a in patients with chronic hepatitis C